A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

December 18, 2012

ViiV Files Regulatory Applications for New Integrase Inhibitor Dolutegravir

ViiV Healthcare announced it has filed regulatory applications for the company’s investigational HIV integrase inhibitor dolutegravir in the United States, Canada and the European Union. The applications seek approval for the new drug to treat HIV among people 12 and older. ViiV has submitted its applications to the U.S. Food and Drug Administration (FDA), Health Canada and the European Medicines Agency.

The pharmaceutical company recently presented Phase III clinical trial data showing dolutegravir (S/GSK1349572) was effective at treating patients with multidrug resistance—specifically, resistance to the integrase inhibitors raltegravir and/or elvitegravir. The drug maintains a relatively low side effect profile, and only 3 percent of study participants discontinued because of adverse effects.

In a statement, ViiV’s chief scientific and medical officer John Pottage, MD, said, “We are encouraged by the comprehensive data package supporting dolutegravir, and believe that it has the potential to offer an important new option for the treatment of both naive and treatment-experienced patients with HIV.”

To read the ViiV release, click here.

Search: HIV, ViiV Healthcare, regulatory application, integrase inhibitor, dolutegravir, U.S. Food and Drug Administration, FDA, , Health Canada, European Medicines Agency, S/GSK1349572, raltegravir, elvitegravir, low side effect profile, John Pottage, treatment-naive, treatment-experienced.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chipper52
    Palm Springs
    California


    RyGuy00
    New York
    New York


    ernienyc
    Bronx
    New York


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.